|Color:||White||Alias:||Orlistat , Orlipastat , Tetrahydrolipstatin|
|Quality Standard:||CP||Packing Specification:||1 Kg/bag, 25kg / Drum|
CAS 96829-58-2 Raw Testosterone Cypionate Powder,
badybuilding Raw Testosterone Cypionate Powder,
CAS 96829-58-2 Weight Losing Raw Materials
Orlistat Weight Loss Powder CAS 96829-58-2 Testosterone Cypionate badybuilding
Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name by Roche in most countries, and is sold over-the-counter as by GlaxoSmithKline in the United Kingdom and the United States.Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini.However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug.
The effectiveness of orlistat in promoting weight loss is clear, albeit moderately. The pooled data from clinical trials show that people who give olivide have less than 2-3 kilograms (4.4-6.6 pounds) of medication than a year, except for changes in lifestyle such as diet and exercise. Is also a modest reduction in blood pressure, it seems to be able to prevent the onset of type 2 diabetes, whether due to weight loss itself or other effects; in a large randomized controlled trial, orlistat he was found in obese people will reduce the incidence of diabetes by nearly 40%.
Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat.After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).
|Description||White Or White-off Crystalline Powder||White Crystalline Powder|
|Specific Rotation||+85°~ +92°||+87.1°|
|Loss On Drying||≤0.50%||0.26%|
|Residue on ignition||≤0.20%||Pass|
Be Conform With USP30 Standard
Contact Person: 张国庆